IO Biotech adopts amended and restated bylaws effective December 13, 2024

IO Biotech, Inc.

Amended bylaws revise procedural mechanics for stockholder director nominations and other business proposals.
New provisions address compliance with Rule 14a-19 under the Exchange Act regarding universal proxy.
Updates to stockholder meeting procedures and director eligibility requirements are included.
Changes conform to recent amendments to the Delaware General Corporation Law.
Other ministerial and clarifying amendments were made effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

IO Biotech, Inc.: Adopted amended and restated bylaws with revisions to stockholder nomination mechanics, Rule 14a-19 compliance, meeting procedures, DGCL conformity, and ministerial changes (effective 2024-12-13).

Change: bylaw amendment
Effective: 2024-12-13

Exact text from the filing

On December 13, 2024, the board of directors (the “Board”) of IO Biotech, Inc. (the “Company”) adopted amended and restated bylaws of the Company (the bylaws, as so amended and restated, the “Amended and Restated Bylaws”), effective immediately.

View on SEC.gov

42 governance changes filed in the last 30 days. Browse all governance changes →

IO Biotech, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-278985

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.